Details for Patent: 7,253,286
✉ Email this page to a colleague
Which drugs does patent 7,253,286 protect, and when does it expire?
Patent 7,253,286 protects LENVIMA and is included in one NDA.
Protection for LENVIMA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has fifty-one patent family members in twenty-three countries.
Summary for Patent: 7,253,286
| Title: | Nitrogen-containing aromatic derivatives |
| Abstract: | Compounds represented by the following general formula: ##STR00001## [wherein A.sup.g is an optionally substituted 5- to 14-membered heterocyclic group, etc.; X.sup.g is --O--, --S--, etc.; Y.sup.g is an optionally substituted C.sub.6-14 aryl group, an optionally substituted 5- to 14-membered heterocyclic group, etc.; and T.sup.g1 is a group represented by the following general formula: ##STR00002## (wherein E.sup.g is a single bond or --N(R.sup.g2)--, R.sup.g1 and R.sup.g2 each independently represent a hydrogen atom, an optionally substituted C.sub.1-6 alkyl group, etc. and Z.sup.g represents a C.sub.1-8 alkyl group, a C.sub.3-8 alicyclic hydrocarbon group, a C.sub.6-14 aryl group, etc.)], salts thereof or hydrates of the foregoing. |
| Inventor(s): | Funahashi; Yasuhiro (Nagoya, JP), Tsuruoka; Akihiko (Tsukuba, JP), Matsukura; Masayuki (Tsukuba, JP), Haneda; Toru (Ushiku, JP), Fukuda; Yoshio (Tsukuba, JP), Kamata; Junichi (Tsukuba, JP), Takahashi; Keiko (Ushiku, JP), Matsushima; Tomohiro (Ushiku, JP), Miyazaki; Kazuki (Tsukuba, JP), Nomoto; Ken-ichi (Tsukuba, JP), Watanabe; Tatsuo (Inzai, JP), Obaishi; Hiroshi (Tsukuba, JP), Yamaguchi; Atsumi (Tsukuba, JP), Suzuki; Sachi (Tsuchiura, JP), Nakamura; Katsuji (Tsukuba, JP), Mimura; Fusayo (Tsukuba, JP), Yamamoto; Yuji (Tsukuba, JP), Matsui; Junji (Toride, JP), Matsui; Kenji (Tsukuba, JP), Yoshiba; Takako (Tsukuba, JP), Suzuki; Yasuyuki (Kagamigahara, JP), Arimoto; Itaru (Tsukuba, JP) |
| Assignee: | Eisai Co., Ltd (Bunkyo-ku, Tokyo, JP) |
| Application Number: | 10/420,466 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; |
Drugs Protected by US Patent 7,253,286
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-001 | Feb 13, 2015 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-002 | Feb 13, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,253,286
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Japan | P2000-320420 | Oct 20, 2000 |
| Japan | P2000-386195 | Dec 20, 2000 |
| Japan | P2001-046685 | Feb 22, 2001 |
International Family Members for US Patent 7,253,286
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1415987 | ⤷ Sign Up | CA 2015 00053 | Denmark | ⤷ Sign Up |
| European Patent Office | 1415987 | ⤷ Sign Up | 15C0070 | France | ⤷ Sign Up |
| European Patent Office | 1415987 | ⤷ Sign Up | 92858 | Luxembourg | ⤷ Sign Up |
| European Patent Office | 1415987 | ⤷ Sign Up | 1590053-3 | Sweden | ⤷ Sign Up |
| European Patent Office | 1415987 | ⤷ Sign Up | CR 2015 00053 | Denmark | ⤷ Sign Up |
| European Patent Office | 1415987 | ⤷ Sign Up | 300764 | Netherlands | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
